NOVOMEDIX LLC — Department of Health and Human Services SBIR Phase II: ENHANCED OVERALL SURVIVAL IN HIGH-RISK PEDIATRIC SOLID TUMORS USING A NOVEL ORAL SMALL MOL
NOVOMEDIX LLC — SBIR Phase II award from Department of Health and Human Services.
Phase II SBIR prototype / development signal
- Phase II is where Department of Health and Human Services funds deeper R&D after feasibility. Incumbents with Phase II history are serious competitors on adjacent topics.
- Use this award as past-performance context and to map customer organizations for STRATFI/TACFI-style transition planning.
- At $2,977,013, this is a large obligation for typical SBIR Phase sizing — worth reviewing for scope breadth and teaming opportunity.
- Tagged technology areas: Human Performance & Medical. Follow those hubs for open topics and peer winners in the same cluster.
Summary
NovoMedix LLC won a $2.98 million NIH Phase II SBIR award to develop a new oral small-molecule drug aimed at improving survival for children with high-risk solid tumors. The project focuses on advancing this novel therapy through later-stage testing.
- Amount
- $2,977,013
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase II
- NAICS
- 541715 · RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
- Place of performance
- CA
- Period
- 2025-09-15 → 2027-09-14
Technology domains
Description
SBIR PHASE II - ENHANCED OVERALL SURVIVAL IN HIGH-RISK PEDIATRIC SOLID TUMORS USING A NOVEL ORAL SMALL MOLECULE